Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

OTHER 3NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 11Head & Neck 5Gastrointestinal 5CNS 4Sarcoma 3Other solid neoplasm 3Gynecologic 3Genitourinary 2Endocrine 2Dermatologic 2Breast 2

Conditions

Ovarian Neoplasms 2Carcinoma, Ovarian Epithelial 2Uterine Cervical Neoplasms 1Recurrent Uterine Corpus Carcinoma 1Fallopian Tube Neoplasms 1

Interventions

Carboplatin 62Paclitaxel 61Specimen Handling 37Cisplatin 37Taxes 35Magnetic Resonance Spectroscopy 31Bevacizumab 30Immunoglobulin G 23Disulfides 23Biopsy 22Cyclophosphamide 19aldesleukin 17Topotecan 16Brachytherapy 16Radiotherapy 15Gemcitabine 15veliparib 14Oxaliplatin 13Doxorubicin 13temsirolimus 12fludarabine 12Platinum 12Docetaxel 121,2-diaminocyclohexaneplatinum II citrate 12olaparib 11liposomal doxorubicin 10cediranib 10Sirolimus 10Radiation 9Nivolumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Gefitinib × Gynecologic × Clear all
NCT00027690 2019-07-23

Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
56 enrolled
Gynecologic

Recurrent Uterine Corpus Carcinoma

NCT00023699 2013-06-24

Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

National Cancer Institute (NCI)

Phase 2 Completed
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00049556 2013-06-20

Gefitinib in Treating Patients With Cervical Cancer

National Cancer Institute (NCI)

Phase 2 Completed
Gynecologic

Carcinoma, Ovarian Epithelial, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡